1.45
+0.06(+4.32%)
Currency In USD
Address
23150 Fashion Drive
Estero, FL 33928
United States of America
Phone
415 592 7399
Website
Sector
Healthcare
Industry
Biotechnology
Employees
2
First IPO Date
February 20, 2025
| Name | Title | Pay | Year Born |
| Surendra K. Ajjarapu | Chief Executive Officer & Executive Chairman | 0 | 1971 |
| Kraig T. Higginson | Interim Chief Executive Officer, President & Executive Chairman of the Board | 0 | 1956 |
| Howard A. Doss | Chief Financial Officer | 0 | 1954 |
| Matthew Ball | Chief Strategy Officer | 0 | 1989 |
| Ernest J. Scheidemann Jr. | Chief Financial Officer | 0 | 1961 |
| Stephen E. Quesenberry | General Counsel & Corporate Secretary | 0 | 1963 |
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.